Market Place
Sourcing Support
Quanterix to Report Q1 2026 Results on May 6, 2026
24 Apr 2026 //
BUSINESSWIRE
Quanterix Debuts Content Innovation Engine at AACR 2026
15 Apr 2026 //
BUSINESSWIRE
Quanterix Corporation Announces Date of 2026 Annual Meeting
27 Mar 2026 //
BUSINESSWIRE
Lucent Diagnostics Partners Nationwide with Life Line Screening
02 Mar 2026 //
BUSINESSWIRE
Quanterix Unveils 2025 Q4 And Full-Year Financials
02 Mar 2026 //
BUSINESSWIRE
Quanterix Submits FDA 510(K) For Multi-Analyte Blood Test
03 Feb 2026 //
BUSINESSWIRE
Quanterix Reveals JAMA Study On Blood-Based Alzheimer`s Risk
21 Jan 2026 //
BUSINESSWIRE
Quanterix Reports Inducement Grants Under Nasdaq LR 5635(C)(4)
16 Jan 2026 //
BUSINESSWIRE
Quanterix Names Everett Cunningham as President & CEO
08 Jan 2026 //
BUSINESSWIRE
Quanterix Alzheimer`s Test Finds Hidden Cases In 40-Year Study
31 Dec 2025 //
FIERCE BIOTECH
Quanterix Study Redefines Alzheimer`s Neuropathology Prevalence
22 Dec 2025 //
BUSINESSWIRE
Quanterix Reveals Board & Leadership Shifts Backing Growth Phase
20 Nov 2025 //
BUSINESSWIRE
Landmark Study: GFAP/NfL in Multiple Sclerosis by Quanterix
17 Nov 2025 //
BUSINESSWIRE
Quanterix Unveils Q3 2025 Financial Results
10 Nov 2025 //
BUSINESS WIRE
Quanterix To Release Q3 2025 Financial Results On Nov 10, 2025
03 Nov 2025 //
BUSINESSWIRE
Quanterix Lab Receives New York State Clinical Laboratory Permit
21 Aug 2025 //
BUSINESSWIRE
Quanterix to Speak at Canaccord Genuity 45th Growth Conference
11 Aug 2025 //
BUSINESSWIRE
Quanterix Announces Q2 2025 Financial Results
07 Aug 2025 //
BUSINESSWIRE
Quanterix To Report Q2 Results On August 7, 2025
04 Aug 2025 //
BUSINESSWIRE
Quanterix Announces Cooperation Agreement with Kent Lake Capital
04 Aug 2025 //
BUSINESSWIRE
Quanterix Introduces p-Tau 205 & 212 Assays for Alzheimer
28 Jul 2025 //
BUSINESSWIRE
Quanterix Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
11 Jul 2025 //
BUSINESSWIRE
Quanterix Acquires Akoya Bio for 1st Biomarker Measuring Platform
08 Jul 2025 //
BUSINESSWIRE
Quanterix Expands Reach with IVD and Large Reference Labs
23 Jun 2025 //
BUSINESSWIRE
Quanterix to Present at Healthcare Conference
06 Jun 2025 //
BUSINESSWIRE
Quanterix releases Q1 2025 financial results
12 May 2025 //
BUSINESSWIRE
Quanterix to Report Q1 2025 Financial Results on May 12, 2025
05 May 2025 //
BUSINESSWIRE
Neurogen, Quanterix Partner On Blood Test For Early Alzheimer’s
19 Feb 2025 //
GLOBENEWSWIRE
Quanterix Provides Update on Financial Performance
14 Jan 2025 //
BUSINESSWIRE
Quanterix to Present at 43rd Annual J.P. Morgan Conference
02 Jan 2025 //
BUSINESSWIRE
Quanterix Releases Preliminary Financial Results for the Q3 of 2024
12 Nov 2024 //
BUSINESSWIRE
Study on Nalmefene, Naloxone for Fentanyl Respiratory Depression
28 Oct 2024 //
BUSINESSWIRE
Quanterix Welcomes Ivana Liebisch to Board of Directors
02 Oct 2024 //
BUSINESSWIRE
Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference
06 Aug 2024 //
BUSINESSWIRE
Quanterix Granted Breakthrough Device Designation for p-Tau 217 Test
04 Mar 2024 //
BUSINESSWIRE
Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference
12 Dec 2023 //
BUSINESSWIRE
Quanterix Releases Operating Results for Third Quarter 2023
06 Nov 2023 //
BUSINESSWIRE
Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test
24 Oct 2023 //
BUSINESSWIRE
Quanterix Announces Agreement for Blood Based Alzheimer`s Disease Detection
23 Oct 2023 //
BUSINESSWIRE
Quanterix launches prescription blood test for Alzheimer’s
10 Jul 2023 //
FIERCE BIOTECH
Quanterix Launches LucentAD Biomarker Blood Test
06 Jul 2023 //
BUSINESSWIRE
Quanterix’s Simoa Technology Drives Advances in Research Presented at CTAD
05 Dec 2022 //
BUSINESSWIRE
Quanterix to Participate in the Trials on Alzheimer’s Disease (CTAD) Task Force
16 Nov 2022 //
BUSINESSWIRE
Quanterix to Participate in the Canaccord MedTech, Diagnostics
10 Nov 2022 //
BUSINESSWIRE
Quanterix Launches First pTau-181 Plasma Laboratory Developed Test
27 Jul 2022 //
BUSINESSWIRE
Quanterix Announces Appointment of Karen A. Flynn to Board of Directors
06 Jun 2022 //
BUSINESSWIRE
Quanterix Granted Breakthrough Device Designation from U.S. FDA
22 Apr 2022 //
BUSINESSWIRE
Quanterix’ Simoa Technology Utilizes sNfL to Assess Disease Activity in MS
04 Apr 2022 //
BUSINESSWIRE
Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation
29 Mar 2022 //
BUSINESSWIRE
Quanterix to Participate in Barclays Global Healthcare Conference
09 Mar 2022 //
BUSINESSWIRE
Quanterix to Participate in Cowen 42nd Annual Health Care Conference On March 9
03 Mar 2022 //
BUSINESSWIRE
Quanterix Announces New Agreements with Lilly to Advance Alzheimer’s Treatment
01 Mar 2022 //
BUSINESSWIRE
Quanterix to Release Q4 and Full Year 2021 Financial Results on March 1, 2022
23 Feb 2022 //
BUSINESSWIRE
Quanterix to Participate in the SVB Leerink Global Healthcare Conference
09 Feb 2022 //
BUSINESSWIRE
UK DRI Biomarker Factory Powers Alzheimer’s Disease Breakthroughs
07 Feb 2022 //
BUSINESSWIRE
Quanterix Provides Operational and Preliminary Financial Highlights
13 Jan 2022 //
BUSINESSWIRE
Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference
06 Jan 2022 //
BUSINESSWIRE
Quanterix shares continue climb following positive FDA news
12 Oct 2021 //
SEEKINGALPHA
FDA Grants BTD to Quanterix`s Blood-Based pTau-181 Assay
11 Oct 2021 //
BIOSPACE
Quanterix Receives Label Expansion on EUA for COVID Antigen Test
13 Sep 2021 //
BUSINESSWIRE
